Given that HK2 plays the crucial role for cell growth in Kras overexpression and p53 function lose-driven lung cancer cells in vitro and in vivo, pharmacologically targeting HK2 may be explored as an effective therapy for NSCLC. This evidence concerns the gene TP53 and non-small cell lung carcinoma.